Graham C. Walker

Education

  • PhD, 1974, University of Illinois
  • BS, 1970, Chemistry, Carleton University

Research Summary

Our research is concentrated in two major areas. First, we aim to understand how the proteins involved in DNA repair, mutagenesis and other cellular responses to DNA damage are regulated. Some of our discoveries have the potential to improve chemotherapy. Second, we probe how nitrogen-fixing nodules develop on legumes, and the relationship between rhizobial functions required for nodule invasion/infection and mammalian pathogenesis.

Awards

  • Revolutionizing Innovative, Visionary Environmental health Research (RIVER), R35 Outstanding Investigator Award, 2017
  • National Academy of Sciences, Member, 2013
  • Howard Hughes Medical Institute, HHMI Professor, 2010
  • University of Guelph, Doctor of Science, honoris causa, 2010
  • American Association for the Advancement of Science, Fellow, 2008
  • Environmental Mutagen Society, EMS Award, 2006
  • American Academy of Arts and Sciences, Fellow, 2004
  • American Cancer Society, Research Professor, 2002
  • Howard Hughes Medical Institute, HHMI Professor, 2002
  • Charles Ross Scholar, 2000-2003
  • American Academy of Microbiology, Fellow, 1994
  • Margaret MacVicar Faculty Fellow, 1992-2002
  • John Simon Guggenheim Memorial Foundation, Guggenheim Fellowship, 1984
  • Massachusetts Institute of Technology, MacVicar Faulty Fellow, 1984
  • Rita Allen Foundation, Career Development Award, 1978
H. Robert Horvitz

Education

  • PhD, 1974, Harvard University
  • BS, 1968, Mathematics and Economics, MIT

Research Summary

Our lab examines how genes control animal development and behavior. We use the experimentally tractable nematode Caenorhabditis elegans to identify and analyze molecular and cellular pathways involved in these important areas of biology. Ultimately, we hope to clarify these fundamental biological mechanisms and provide further insight into human disease.

Awards

  • U.S. National Academy of Inventors, Member, 2015
  • American Association for Cancer Research Academy, Fellow, 2013
  • Royal Society of London, Foreign Member, 2009
  • Genetics Society (U.K.), Mendel Medal, 2007
  • Eli Lilly Lecturer Award, 2007
  • Massachusetts Institute of Technology, James R Killian Jr Faculty Achievement Award, 2006
  • National Academy of Medicine, Member, 2003
  • American Cancer Society, Medal of Honor, 2002
  • The Nobel Foundation, Nobel Prize in Physiology or Medicine, 2002
  • Bristol-Myers Squibb, Award for Distinguished Achievement in Neuroscience, 2001
  • March of Dimes, Developmental Biology, 2000
  • Gairdner Foundation, Gairdner Foundation International Award, 1999
  • National Academy of Sciences, Member, 1991
  • American Academy of Arts and Sciences, Fellow, 1989
  • American Association for the Advancement of Science, Fellow, 1989
  • Howard Hughes Medical Institute, HHMI Investigator, 1988
Peter Reddien

Education

  • PhD, 2002, MIT
  • SB, 1996, Molecular Biology, University of Texas at Austin

Research Summary

We investigate how stem cells are regulated to regenerate missing tissues. We study the cellular events involved in this process and the attendant roles for regulatory genes that control regeneration steps. We utilize an array of methodologies, including high-throughput sequencing, RNA interference (RNAi) screening, and numerous assays and tools for phenotypic analysis to characterize regeneration regulatory genes.

Awards

  • Howard Hughes Medical Institute, HHMI Investigator, 2013
David C. Page

Education

  • MD, 1984, Harvard Medical School
  • BS, 1978, Chemistry, Swarthmore College

Research Summary

We seek to understand the genetic differences between males and females — both within and beyond the reproductive tract. We study the medical ramifications of these differences in a broad context, through comparative biological, evolutionary, developmental and clinically focused analyses. Our three main veins of research relate to sex differences in health and disease, sex chromosome genomics, and germ cell origins and development.

Awards

  • American Academy of Arts and Sciences, Fellow, 2012
  • March of Dimes, Developmental Biology, 2011
  • National Academy of Medicine, Member, 2008
  • National Academy of Sciences, Member, 2005
  • Howard Hughes Medical Institute, HHMI Investigator, 1990
  • MacArthur Foundation, MacArthur Fellowship, 1986
David Bartel

Education

  • PhD, 1993, Harvard University
  • BA, 1982, Biology, Goshen College

Research Summary

We study microRNAs and other small RNAs that specify the destruction and/or translational repression of mRNAs. We also study mRNAs, focusing on their untranslated regions and poly(A) tails, and how these regions recruit and mediate regulatory phenomena.

Awards

  • National Academy of Sciences, Member, 2011
  • Howard Hughes Medical Institute, HHMI Investigator, 2005
  • National Academy of Sciences Award in Molecular Biology, 2005
  • AAAS Newcomb Cleveland Prize, 2002
David Housman

Education

  • PhD, 1971, Brandeis University
  • BS, 1966, Biology, Brandeis University

Research Summary

We use genetic approaches to identify the molecular basis of human disease pathology. More specifically, we develop strategies to combat three major disease areas: cancer, trinucleotide repeat disorders like Huntington’s disease, and cardiovascular disease.

Awards

  • National Academy of Medicine, Member, 1997
  • National Academy of Sciences, Member, 1994
Leonard P. Guarente

Education

  • PhD, 1978, Harvard University
  • SB, 1974, Biology, MIT

Research Summary

We combine comprehensive bioinformatics analyses with functional analyses of pathways and genes to study aging in humans and mice. We apply these approaches to identify the major pathways and genes involved in the aging of certain brain regions. We are also studying muscular dystrophy and muscle loss with aging. Ultimately, our findings may guide studies in other organs and lead to a systemic understanding of mammalian aging.

Awards

  • Miami Winter Symposium, Feodor Lynen Award, 2012
  • University of Toronto, Charles H. Best Lectureship and Award, 2011
  • Dart/NYU Biotechnology, Achievement Award, 2009
  • French Academie des Sciences, Elected, 2009
  • American Academy of Arts and Sciences, Fellow, 2004
Tyler Jacks

Education

  • PhD, 1988, University of California, San Francisco
  • SB, 1983, Biology, Harvard University

Research Summary

Dr. Jacks’ research has focused on developing new methods for the construction and characterization of genetically engineered mouse models or GEMMs of human cancer, and recently has moved into the burgeoning area of tumor immunology to understand the interactions between the immune system and cancer.  His group has produced GEMMs with constitutive and conditional mutations in several tumor suppressor genes, oncogenes, and genes involved in oxidative stress, DNA repair and epigenetic control of gene expression. These GEMMS have been used to examine the mechanism of tumor initiation and progression, to uncover the molecular, genetic and biochemical relationship to the human diseases, as tools to study response and resistance to chemotherapy, and to explore methods in molecular imaging and early detection of cancer.

Awards

  • AACR Princess Takamatsu Memorial Lectureship, 2020
  • Massachusetts Institute of Technology, James R Killian Jr Faculty Achievement Award, 2015
  • Sergio Lombroso Award in Cancer Research, 2015
  • American Academy of Arts and Sciences, Fellow, 2012
  • National Academy of Sciences, Member, 2009
  • Institute of Medicine of the National Academies, Member, 2009
  • Paul Marks Prize for Cancer Research, 2005
  • Howard Hughes Medical Institute, HHMI Investigator, 1994
Gerald R. Fink

Education

  • PhD, 1965, Yale University
  • BA, 1962, Biology, Amherst College

Research Summary

We study the molecules that allow fungi to penetrate tissues and grow in a hostile environment. Using genetics, biochemistry and genomics, we answer questions such as:  What makes Candida albicans such a successful pathogen?  How do fungal pathogens evolve antibiotic resistance? How do they manage to change their genetic composition so rapidly?

The Fink lab is no longer accepting students.

Awards

  • Thomas Hunt Morgan Medal, Genetics Society of America, 2020
  • James R. Killian Jr. Faculty Achievement Award, 2018
  • American Association for the Advancement of Science, Fellow, 2015
  • Gruber International Prize in Genetics, 2010
  • American Philosophical Society, 2003
  • Yeast Genetics and Molecular Biology – Lifetime Achievement Award, 2002
  • George W. Beadle Award, Genetics Society of America, 2001
  • Ellison Medical Foundation, Senior Scholar Award, 2001
  • National Academy of Medicine, 1996
  • Wilbur Lucius Cross Medal, Yale University, 1992
  • Emil Christian Hansen Foundation Award for Microbiology, Denmark, 1986
  • American Academy of Arts and Sciences, Fellow, 1984
  • Yale Science and Engineering Award, 1984
  • National Academy of Sciences, Member, 1981
  • National Academy of Sciences Award in Molecular Biology, 1981
  • John Simon Guggenheim Memorial Foundation, Guggenheim Fellowship, 1974
Revealing an imperfect actor in plant biotechnology

Whitehead Institute researchers detect the chemical mistakes of a common herbicide-resistance enzyme, then successfully re-engineer it for enhanced precision.

Nicole Davis | Whitehead Institute
November 29, 2017

A research team led by MIT’s Whitehead Institute for Biomedical Research has harnessed metabolomic technologies to unravel the molecular activities of a key protein that enables plants to withstand a common herbicide.

Their findings reveal how the protein — a kind of catalyst or enzyme first isolated in bacteria and introduced into plants such as corn and soybeans in the 1990s — can sometimes act imprecisely, and how it can be successfully re-engineered to be more precise. The new study, which appears online in the journal Nature Plants, raises the standards for bioengineering in the 21st century.

“Our work underscores a critical aspect of bioengineering that we are now becoming technically able to address,” says senior author Jing-Ke Weng, a member of the Whitehead Institute and an assistant professor of biology at MIT. “We know that enzymes can behave indiscriminately. Now, we have the scientific capabilities to detect their molecular side effects, and we can leverage those insights to design smarter enzymes with enhanced specificity.”

Plants provide an extraordinary model for scientists to study how metabolism changes over time. Because they cannot escape from predators or search for new food sources when supplies run low, plants must often grapple with an array of environmental insults using what is readily available — their own internal biochemistry.

“Although they appear to be stationary, plants have rapidly evolving metabolic systems,” Weng explains. “Now, we can gain an unprecedented view of these changes because of cutting-edge techniques like metabolomics, allowing us to analyze metabolites and other biochemicals on a broad scale.”

Key players in this evolutionary process, and a major focus of research in Weng’s laboratory, are enzymes. Traditionally, these naturally occurring catalysts have been viewed as mini-machines, taking the proper starting material (or substrate) and flawlessly converting it to the correct product. But Weng and other scientists now recognize that they make mistakes, often by latching on to an unintended substrate.

“This concept, known as enzyme promiscuity, has a variety of implications, both in enzyme evolution and more broadly, in human disease,” Weng says.

It also has implications for bioengineering, as Bastien Christ, a postdoctoral fellow in Weng’s laboratory, and his colleagues recently discovered.

Christ, then a graduate student in Stefan Hörtensteiner’s lab at the University of Zurich in Switzerland, was studying a particular strain of the flowering plant Arabidopsis thaliana as part of a separate project when he made a puzzling observation. He found that two biochemical compounds were present at unusually high levels in the plant’s leaves.

Strangely, these compounds (called acetyl-aminoadipate and acetyl-tryptophan) weren’t present in any of the normal, so-called wild type plants. As he and his colleagues searched for an explanation, they narrowed in on the source: an enzyme, called BAR, that was engineered into the plants as a kind of chemical beacon, enabling scientists to more readily study them.

But BAR is more than just a tool for scientists. It is also one of the most commonly deployed traits in genetically modified crops such as soybeans, corn, and cotton, enabling them to withstand a widely-used herbicide (known as phosphinothricin or glufosinate).

For decades, scientists have known that BAR, originally isolated from bacteria, can render the herbicide inactive by tacking on a short string of chemicals, made of two carbons and one oxygen (also called an acetyl group). As the researchers describe in their Nature Plants paper, BAR has a promiscuous side, and can work on other substrates, too, such as the amino acids tryptophan and aminoadipate (a lysine derivative).

That explains why they can detect the unintended products (acetyl-tryptophan and acetyl-aminoadipate) in crops genetically engineered to carry BAR, such as soybeans and canola.

Their research included detailed studies of the BAR protein, including crystal structures of the protein bound to its substrates. This provided them with a blueprint for how to strategically modify BAR to make it less promiscuous, and favor only the herbicide as a substrate and not the amino acids. Christ and his colleagues created several versions that lack the non-specific activity of the original BAR protein.

“These are natural catalysts, so when we borrow them from an organism and put them into another, they may not necessarily be perfect for our purposes,” Christ says. “Gathering this kind of fundamental knowledge about how enzymes work and how their structure influences function can teach us how to select the best tools for bioengineering.”

There are other important lessons, too. When the BAR trait was first evaluated by the U.S. Food and Drug Administration (FDA) in 1995 for use in canola, and in subsequent years for other crops, metabolomics was largely non-existent as a technology for biomedical research. Therefore, it could not be applied toward the characterization of genetically engineered plants and foods, as part of their regulatory review. Nevertheless, acetyl-aminoadipate and acetyl-tryptophan, which are normally present in humans, have been reviewed by the FDA and are safe for human and animal consumption.

Weng and his colleagues believe their study makes a strong case for considering metabolomics analyses as part of the review process for future genetically engineered crops.

“This is a cautionary tale,” Weng says.

The work was supported by the Swiss National Science Foundation, the EU-funded Plant Fellows program, the Pew Scholar Program in the Biomedical Sciences, and the Searle Scholars Program.